Zobrazeno 1 - 10
of 357
pro vyhledávání: '"Leleu, A."'
Autor:
Hani Hassoun, Jacob P. Laubach, Jan S. Moreb, Sara Thuresson, Paula Rodriguez-Otero, Marcus Thuresson, Michele Cavo, Albert Oriol, Maria-Victoria Mateos, Joan Bladé, John W. Hiemenz, Adrian Alegre, Amitabha Mazumder, Horizon (Op ) Investigators, Kenneth C. Anderson, Omar Nadeem, Johan Harmenberg, Nicolaas A Bakker, Xavier Leleu, Alessandra Larocca, Christopher Maisel, Paul G. Richardson, Agne Paner, Anastasios Raptis, Cyrille Touzeau, Catriona Byrne
Publikováno v:
Journal of Clinical Oncology
Journal of Clinical Oncology, 2021, 39 (7), pp.757-767. ⟨10.1200/JCO.20⟩
Journal of Clinical Oncology, American Society of Clinical Oncology, 2021, 39 (7), pp.757-767. ⟨10.1200/JCO.20⟩
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
Journal of Clinical Oncology, 2021, 39 (7), pp.757-767. ⟨10.1200/JCO.20⟩
Journal of Clinical Oncology, American Society of Clinical Oncology, 2021, 39 (7), pp.757-767. ⟨10.1200/JCO.20⟩
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
PURPOSE Melphalan flufenamide (melflufen) is a first-in-class peptide-drug conjugate that targets aminopeptidases and rapidly and selectively releases alkylating agents into tumor cells. The phase II HORIZON trial evaluated the efficacy of melflufen
Autor:
Daniel Curnier, Louise Leleu, Tarik Hafyane, Farida Cheriet, Daniel Sinnett, Mohamed Aissiou, Delphine Périé, Caroline Laverdière, Gregor Andelfinger, Maxime Caru, Maja Krajinovic
Publikováno v:
The International Journal of Cardiovascular Imaging. 38:873-882
Doxorubicin leads to dose-dependent cardiotoxicity in childhood acute lymphoblastic leukemia (ALL) survivors. The first aim was to propose a contour-based estimation of T1 and T2 relaxation times based on the myocardial area, while our second aim was
Autor:
Shaji Kumar, Maria Delioukina, Torben Plesner, Noopur Raje, Jessica Vermeulen, Hartmut Goldschmidt, Supratik Basu, Hang Quach, Rian Van Rampelbergh, Saad Z. Usmani, Xavier Leleu, Aurore Perrot, Thierry Facon, Jianping Wang, Tahamtan Ahmadi, Michael O'Dwyer, Clarissa M. Uhlar, Katja Weisel, Cyrille Hulin, Robert Z. Orlowski, Brenda Tromp, Philippe Moreau, Christopher P. Venner, Joseph R. Mace, Mourad Tiab, Margaret Macro, Laurent Frenzel, Hareth Nahi, Nizar J. Bahlis
Publikováno v:
Facon, T, Kumar, S K, Plesner, T, Orlowski, R Z, Moreau, P, Bahlis, N, Basu, S, Nahi, H, Hulin, C, Quach, H, Goldschmidt, H, O'Dwyer, M, Perrot, A, Venner, C P, Weisel, K, Mace, J R, Raje, N, Tiab, M, Macro, M, Frenzel, L, Leleu, X, Ahmadi, T, Wang, J, Van Rampelbergh, R, Uhlar, C M, Tromp, B, Delioukina, M, Vermeulen, J & Usmani, S Z 2021, ' Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA) : overall survival results from a randomised, open-label, phase 3 trial ', The Lancet Oncology, vol. 22, no. 11, pp. 1582-1596 . https://doi.org/10.1016/S1470-2045(21)00466-6
Background: In the primary analysis of the phase 3 MAIA trial (median follow-up 28·0 months), a significant improvement in progression-free survival was observed with daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethas
Autor:
Anita Zahlten-Kumeli, Katja Weisel, Xavier Leleu, David S. Siegel, Bifeng Ding, Rohan Medhekar
Publikováno v:
Leukemia & Lymphoma. 62:3002-3010
CANDOR (NCT03158688) compared carfilzomib, dexamethasone, and daratumumab (KdD) to carfilzomib and dexamethasone (Kd) in patients with relapsed/refractory multiple myeloma (RRMM). A secondary objective of CANDOR was to evaluate health-related quality
Autor:
Hans C. Lee, Saad Z. Usmani, Robert M. Rifkin, Dasha Cherepanov, Evangelos Terpos, Faith E. Davies, Dorothy Romanus, Antonio Palumbo, Aditya Raju, Jesus G. Berdeja, Dawn Marie Stull, Noemi Puig, Jorge Vela-Ojeda, Rafat Abonour, Xavier Leleu, Hui Huang, Ajai Chari, Eileen Farrelly, Mario Boccadoro, Gordon Cook, Katja Weisel, Gareth J. Morgan, Caitlin Costello, Jeffrey A. Zonder, Marlo Blazer, Michael A. Thompson, Roman Hájek
Publikováno v:
Annals of Hematology
Multiple available combinations of proteasome inhibitors, immunomodulators (IMIDs), and monoclonal antibodies are shifting the relapsed/refractory multiple myeloma (RRMM) treatment landscape. Lack of head-to-head trials of triplet regimens highlights
Autor:
Michel Attal, Xavier Leleu, Salomon Manier, Lotfi Benboubker, Clara Mariette, Cécile Sonntag, Karim Belhadj, Denis Caillot, Cyrille Touzeau, Martine Escoffre-Barbe, Benjamin Hebraud, Laurent Garderet, Soraya Wuilleme, Philippe Moreau, Jill Corre, Valérie Lauwers-Cances, Thierry Facon, Jehan Dupuis, Murielle Roussel
Publikováno v:
Blood. 138:113-121
Bortezomib, lenalidomide, and dexamethasone plus transplant is a standard of care for eligible patients with multiple myeloma. Because responses can deepen with time, regimens with longer and more potent induction/consolidation phases are needed. In
Autor:
Xavier Leleu, Waltraud Pasteiner, Peter I. Croucher, Yang Wang, Evangelos Terpos, Charlotte Pawlyn, Anthony Glennane, Noopur Raje, Jude Canon, Ramón García-Sanz
Publikováno v:
Blood Adv
An exploratory end point from a recent trial in patients with newly diagnosed multiple myeloma showed that median progression-free survival (PFS) was increased by 10.7 months with denosumab vs zoledronic acid. We performed additional analyses to iden
Autor:
Giebel, Sebastian, Labopin, Myriam, Sobczyk-Kruszelnicka, Malgorzata, Stelljes, Matthias, Byrne, Jenny, Fegueux, Nathalie, Beelen, Dietrich, Rovira, Montserrat, Spyridonidis, Alexandros, Blaise, Didier, Bornhäuser, Martin, Karadogan, Ihsan, Savani, Bipin, Nagler, Arnon, Mohty, Mohamad, Martin, Sonja, Chevallier, Patrice, Neubauer, Andreas, Damaj, Gandhi, Koc, Yener, Ganser, Arnold, Collin, Matthew, Yakoub-Agha, Ibrahim, Ozdogu, Hakan, Araujo, Mercedes Colorado, Itäla-Remes, Maija, Orchard, Kim, Isaksson, Cecilia, Bethge, Wolfgang, Martin, Hans, Aljurf, Mahmoud, Faber, Edgar, Caballero, Dolores, Zák, Pavel, Leleu, Xavier, Bay, Jacques-Olivier, Rohrlich, Pierre-Simon, Kröger, Nicolaus, Huynh, Anne, Schäfer-Eckart, Kerstin, Milpied, Noel, Lenhoff, Stig, Ho, Aloysius, López, Jose Luis Bello, Mordini, Nicola, Lioure, Bruno, Halaburda, Kazimierz, Olivieri, Attilio, Gedde-Dahl, Tobias, Protheroe, Rachel, Tischer, Johanna, Klammer, Matthias, Clausen, Johannes, Potter, Victoria, Ladetto, Marco, Tilly, Herve, Deconinck, Eric, Brecht, Arne, Müller, Lutz Peter, Heinicke, Thomas, Carrete, Juan Pio Torres, Bazarbachi, Ali, Reményi, Péter, Rubio, Marie Thérèse, Fanin, Renato, Pérez-Simón, Jose Antonio, Niels, Murawski, Diez-Martin, J., Arat, Mutlu, Hermine, Olivier, Socié, Gerard, Cornelissen, Jan, Santarone, Stella, Guyotat, Denis, Bulabois, Claude Eric, Bernasconi, Paolo, Johansson, Jan-Erik, Vrhovac, Radovan, Greinix, Hildegard, Lorenzo, José Luis López, Apte, Shashikant, Craddock, Charles, Kobbe, Guido, Zahrani, Mohsen Al, Dreger, Peter, Lange, Andrzej, Tbakhi, Abdelghani, Meijer, Ellen, Llamas, Carlos Vallejo, Santasusana, Josep Maria Ribera, Corradini, Paolo, Benedetti, Fabio, Rambaldi, Alessandro, Gandemer, Virginie, Malfuson, Jean-Valère, Kaare, Ain, Risitano, Antonio, Petrini, Mario, Selleri, Carmine, Wu, Depei
Publikováno v:
Bone Marrow Transplantation, 56(2), 481-491. Nature Publishing Group
Giebel, S, Labopin, M, Sobczyk-Kruszelnicka, M, Stelljes, M, Byrne, J L, Fegueux, N, Beelen, D W, Rovira, M, Spyridonidis, A, Blaise, D, Bornhäuser, M, Karadogan, I, Savani, B N, Nagler, A, Mohty, M & Principal investigators of the contributing institutions 2021, ' Total body irradiation + fludarabine compared to busulfan + fludarabine as “reduced-toxicity conditioning” for patients with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation in first complete remission: a study by the Acute Leukemia Working Party of the EBMT ', Bone Marrow Transplantation, vol. 56, no. 2, pp. 481-491 . https://doi.org/10.1038/s41409-020-01050-7
Bone Marrow Transplantation
Bone Marrow Transplantation, 2021, 56 (2), pp.481-491. ⟨10.1038/s41409-020-01050-7⟩
Giebel, S, Labopin, M, Sobczyk-Kruszelnicka, M, Stelljes, M, Byrne, J L, Fegueux, N, Beelen, D W, Rovira, M, Spyridonidis, A, Blaise, D, Bornhäuser, M, Karadogan, I, Savani, B N, Nagler, A, Mohty, M & Principal investigators of the contributing institutions 2021, ' Total body irradiation + fludarabine compared to busulfan + fludarabine as “reduced-toxicity conditioning” for patients with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation in first complete remission: a study by the Acute Leukemia Working Party of the EBMT ', Bone Marrow Transplantation, vol. 56, no. 2, pp. 481-491 . https://doi.org/10.1038/s41409-020-01050-7
Bone Marrow Transplantation
Bone Marrow Transplantation, 2021, 56 (2), pp.481-491. ⟨10.1038/s41409-020-01050-7⟩
International audience; The optimal conditioning for patients with acute myeloid leukemia in first complete remission treated with allogeneic hematopoietic cell transplantation (allo-HCT) has not been defined so far. In this retrospective study, we c
Autor:
Richard Leblanc, Marie-Laure Risse, Xavier Leleu, Ludek Pour, Chang-Ki Min, Marta Segura, Mehmet Turgut, Sandrine Schwab, Ross I. Baker, Thomas G. Martin, Marcelo Capra, Laure Malinge, Philippe Moreau, Mohamad Mohty, Meletios A. Dimopoulos
Publikováno v:
Haematologica
Haematologica, Ferrata Storti Foundation, 2020, ⟨10.3324/haematol.2021.279229⟩
Haematologica, Ferrata Storti Foundation, 2020, ⟨10.3324/haematol.2021.279229⟩
Introduction: Renal impairment (RI) is a common feature in multiple myeloma (MM) and an adverse predictor of survival. Anti-myeloma treatments that can also improve renal function in patients (pts) with MM are required. Isatuximab (Isa), a monoclonal
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8a2c6711c32d83933231e6ce93067ae2
https://hal.sorbonne-universite.fr/hal-03388173
https://hal.sorbonne-universite.fr/hal-03388173
Autor:
Ashraf Badros, Nizar J. Bahlis, Roman Hájek, Larry D. Anderson, Vadim A Doronin, Meletios A. Dimopoulos, Jacqueline Jeha, Halyna Pylypenko, Jatin P. Shah, Reuben Benjamin, Sebastian Grosicki, Maria Gavriatopoulou, Dinesh Kumar Sinha, Xavier Leleu, Thierry Facon, Tuphan Kanti Dolai, Michele Cavo, Don A. Stevens, Moshe Yair Levy, Iryna Kriachok, Sundar Jagannath, L. Pour, Paul G. Richardson, Holger W. Auner, Maria V. Mateos, Sharon Shacham, Sosana Delimpasi, Hang Quach, Yi Chai, Mamta Garg, Michael Kauffman, Ivan Spicka, Maryana Simonova, Philippe Moreau, Christopher P. Venner, Ganna Usenko, Melina Arazy
Publikováno v:
Journal of Hematology & Oncology
Journal of Hematology & Oncology, Vol 14, Iss 1, Pp 1-5 (2021)
Journal of Hematology & Oncology, Vol 14, Iss 1, Pp 1-5 (2021)
Therapeutic regimens for previously treated multiple myeloma (MM) may not provide prolonged disease control and are often complicated by significant adverse events, including peripheral neuropathy. In patients with previously treated MM in the Phase
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aaf7cc61cc2d359ff206c62213e34e08
http://hdl.handle.net/10044/1/89189
http://hdl.handle.net/10044/1/89189